Posts Tagged ‘lung cancer’
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…
Read MoreAndarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 26, 2018— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration…
Read MoreAndarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
The Andarix drug addresses the growing Lung Cancer problem in Asia SOMERVILLE, Mass.— July 10, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto,…
Read MoreAndarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Targeting Lung Cancer in Rare Disease Patient Populations SOMERVILLE, MA— June 25, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29…
Read MoreAndarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference
Personalized Medicine for Small Cell Lung Cancer SOMERVILLE, Mass.— January 29, 2018 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018. The conference will focus…
Read MoreAndarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting
Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —January 8, 2018— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of…
Read MoreAndarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA
Targeted Tozaride Drug Therapy is effective for Small Cell Lung Cancer SOMERVILLE, Mass.— July 24, 2017 — Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017.…
Read MoreAndarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market
Tozaride has demonstrated clinical effectiveness in treating lung cancer SOMERVILLE, Mass.— September 6, 2017— Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights…
Read MoreAndarix Pharmaceuticals Announces Publication of Abstract Describing Lung Cancer Clinical Trial Results at ASCO 2017 Annual Meeting
Targeted Tozaride Drug Therapy for Small Cell Lung and neuroendocrine Cancer SOMERVILLE, Mass.— June 2, 2017 — Andarix Pharmaceuticals, a clinical stage company, announced today the publication of results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. The abstract will be presented at the annual American Society of Clinical Oncology (ASCO)…
Read MoreAndarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study
Tozaride Demonstrates Significant Tumor Reduction in Clinical Study SOMERVILLE, Mass.—May 2, 2017— Andarix Pharmaceuticals, a clinical stage company, announced today the results of a phase1/2 clinical study in lung and neuroendocrine cancer patients. In an open label, single arm study, refractory lung cancer patients to standard of care therapy were identified by image analysis using…
Read More